Document is current
Any future updates will be listed below
-
Authors
Balbach, Melanie
Rossetti, Thomas
Ferreira, Jacob
Ghanem, Lubna
Ritagliati, Carla
Myers, Robert W.
Huggins, David J.
Steegborn, Clemens http://orcid.org/0000-0002-0913-1467
Miranda, Ileana C. http://orcid.org/0000-0003-3168-0515
Meinke, Peter T.
Buck, Jochen http://orcid.org/0000-0002-3568-5869
Levin, Lonny R. http://orcid.org/0000-0002-5204-6356
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD100549, HD088571)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
- License Information
-
More Information
Article History
Received: 14 September 2022
Accepted: 17 January 2023
First Online: 14 February 2023
Competing interests
: Drs. Buck and Levin have licensed the commercialization of a panel of monoclonal antibodies directed against sAC to Millipore. Drs. Meinke, Steegborn, Levin, and Buck are co-founders of Sacyl Pharmaceuticals, Inc. established to develop sAC inhibitors into on-demand contraceptives. M.B., C.S., J.B., L.R.L., and employees of the Tri-Institutional Therapeutics Discovery Institute (TDI) may benefit from the further development and licensure of molecules described herein. All other authors declare no competing interests.
